Table 3.
Results of univariate and multivariate Cox regression analysis for overall survival
| Odds Ratio (95% Confidence Interval), p | ||
|---|---|---|
| Univariate | Multivariate | |
| Clinical | ||
| Age | ||
| <50 years | - | |
| 50-70 years | 0.89 (0.59-1.34), 0.59 | |
| >70 years | 1.09 (0.70-1.70), 0.70 | |
| Male Sex | 1.22 (0.97-1.53), 0.09 | 1.09 (0.82-1.45), 0.54 |
| Radiographic Staging | ||
| Potentially Resectable | - | |
| Borderline Resectable | 0.86 (0.63-1.17), 0.34 | |
| Locally Advanced | 0.76 (0.48-1.20), 0.23 | |
| Year of Surgery | ||
| 1999-2004 | - | |
| 2005-2009 | 0.90 (0.70-1.17), 0.45 | |
| 2010-2015 | 0.84 (0.62-1.14), 0.25 | |
| Pre-Treatment CA 19-9 | 1.29 (1.03-1.62), 0.03 | 1.04 (0.79-1.37), 0.78 |
| Neoadjuvant Chemotherapy | 1.15 (0.92-1.45), 0.22 | |
| Sensitizing Chemotherapy | ||
| Gemcitabine | - | |
| Capecitabine/5-Fluorouracil | 1.28 (1.01-1.62), 0.04 | 1.31 (1.0-1.73), 0.053 |
| XRT | ||
| 30Gy | - | |
| 50.4Gy | 0.91 (0.72-1.15), 0.42 | 0.93 (0.71-1.22), 0.60 |
| None | 1.21 (0.74-1.97), 0.45 | 1.24 (0.16-9.50), 0.84 |
| Adjuvant Chemotherapy | 0.94 (0.73-1.20), 0.60 | |
|
| ||
| Surgical | ||
| EBL | ||
| ≤500 mL | - | - |
| >500-1000 mL | 1.20 (0.93-1.55), 0.16 | 1.11 (0.81-1.52), 0.51 |
| >1000 mL | 1.61 (1.19-2.18), 0.002 | 1.42 (0.98-2.07), 0.07 |
| Vascular Resection | 1.55 (1.24-1.95), <0.001 | 1.46 (1.09-1.94), 0.01 |
| Lymph Nodes Excised | ||
| <15 | - | |
| 15-30 | 1.02 (0.72-1.43), 0.93 | |
| >30 | 1.00 (0.67-1.49), 1.0 | |
|
| ||
| Pathology | ||
| Tumor Size | 1.15 (1.07-1.25), <0.001 | 0.95 (0.86-1.07), 0.40 |
| Differentiation | ||
| Well/Moderate | - | - |
| Poor | 1.34 (1.05-1.71), 0.02 | 1.37 (1.02-1.83), 0.03 |
| Margin Status | ||
| R0 | - | - |
| R1 | 2.07 (1.62-2.65), <0.001 | 1.37 (1.01-1.86), 0.04 |
| SMA Margin Length | ||
| 0 mm | - | |
| >0-1.0 mm | 1.08 (0.65-1.80), 0.77 | |
| >1.0-5.0 mm | 0.67 (0.41-1.09), 0.11 | |
| >5.0 mm | 0.43 (0.26-0.71), 0.001 | |
| Positive Lymph Nodes | 1.87 (1.48-2.35), <0.001 | 1.40 (1.04-1.90), 0.03 |
| Percentage of Viable Cells | ||
| 0 | - | - |
| >0-5% | 1.62 (0.63-4.2), 0.32 | 1.62 (0.21-12.52), 0.65 |
| >5-10% | 2.38 (0.94-6.04), 0.07 | 1.89 (0.25-14.45), 0.54 |
| >10-30% | 2.85 (1.16-7.0), 0.02 | 1.91 (0.25-14.49), 0.53 |
| >30% | 2.73 (1.12-6.66), 0.03 | 1.69 (0.22-12.99), 0.62 |
| Lymph Node Ratio | ||
| 0 | - | |
| 0-0.2 | 1.61 (1.25-2.06), <0.001 | |
| ≥0.2 | 3.36 (2.42-4.65), <0.001 | |
| Lymphovascular Invasion | 1.75 (1.38-2.22), <0.001 | 1.08 (0.79-1.46), 0.63 |
| Perineural Invasion | 2.50 (1.80-3.49), <0.001 | 1.84 (1.21-2.80), 0.004 |